Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck : Updated Results for Investigational Therapy Tepotinib Presented at WCLC 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2019 | 08:37am EDT

Not intended for UK-based media

  • Results include progression-free survival and overall survival data from Phase Ib/II INSIGHT study
  • Phase II INSIGHT 2 study now open for enrollment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation and select MET dysregulations

Merck KGaA, Darmstadt, Germany, a leading science and technology company, which operates its biopharmaceutical business as EMD Serono in the US and Canada, announced today important milestones for two combination studies of the investigational therapy tepotinib* in locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation and select MET dysregulations. These include progression-free survival (PFS) and overall survival (OS) data from the Phase Ib/II INSIGHT study of tepotinib plus the EGFR inhibitor gefitinib, and an update that the Phase II INSIGHT 2 study of tepotinib plus tyrosine kinase inhibitor (TKI) osimertinib is now open for enrollment. Tepotinib, discovered in-house at Merck KGaA, Darmstadt, Germany, is an investigational oral MET inhibitor that underscores Merck KGaA, Darmstadt, Germany's strategic focus on delivering innovative precision medicines to patients with cancer.

'The consistency of resultsacross the clinical development program fortepotinib continues to highlight the potential for this investigational therapy in targeting select NSCLC mutations and alterations that are associated with aggressive tumor behavior and poor clinical prognosis,' said Luciano Rossetti, Global Head of Research & Development for the Biopharma business of Merck KGaA, Darmstadt, Germany. 'We are committed to progressing tepotinib as part of our precision medicine strategy and our work to deliver new therapeutic options for people living with difficult-to-treat cancers, including NSCLC.'

Data were presented on September 8 at the 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC19), including 18-month follow-up data from the Phase Ib/II INSIGHT study evaluating tepotinib in combination with the EGFR inhibitor gefitinib compared with standard chemotherapy in patients with EGFR-mutant locally advanced or metastatic NSCLC with MET protein overexpression or MET gene amplification who had disease progression after receiving an EGFR TKI. These results include updated PFS data as well as the first OS data for patients in both the MET overexpression and MET amplification cohorts of this study. These data will be submitted for future publication in a medical journal.

Additionally, Merck KGaA, Darmstadt, Germany today announced it is enrolling patients in the Phase II INSIGHT 2 study investigating tepotinib in combination with the TKI osimertinib in patients with EGFR-mutated, MET-amplified, locally advanced or metastatic NSCLC with acquired resistance to prior EGFR TKI therapy. The decision to initiate the INSIGHT 2 study is based on the encouraging findings seen in the Phase Ib/II INSIGHT study. Early data from this study presented at the 2019 American Association for Cancer Research Annual Meeting demonstrated clinical anti-tumor activity for the combination of tepotinib plus gefitinib compared with chemotherapy in patients with EGFR-mutant locally advanced or metastatic NSCLC with MET gene amplification who had disease progression after receiving an EGFR TKI, based on both investigator assessment and independent review committee assessment. Related grade ≥3 treatment-emergent adverse events (TEAEs) were reported in 6 (50.0%) patients treated with tepotinib plus gefitinib and 5 (71.4%) patients receiving chemotherapy. The most common related TEAEs in the tepotinib plus gefitinib arm were diarrhea (50.0%) and amylase increased (41.7%) and in the chemotherapy arm were anemia (57.1%), white blood cell count decreased (57.1%), neutrophil count decreased (57.1%) and nausea (42.9%). No new safety signals were observed.1 These data also indicate that MET amplification may be a biomarker predictive of response to tepotinib.

Tepotinib is also being investigated in the ongoing Phase II VISION study, evaluating tepotinib in advanced or metastatic NSCLC patients harboring MET alterations (MET exon 14 skipping alterations and MET amplifications) as monotherapy. Results from this study were presented in an oral presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.2 In March 2018, tepotinib's potential was recognized by the Japanese Ministry of Health, Labour and Welfare (MHLW), which granted SAKIGAKE 'fast-track' designation for tepotinib in advanced NSCLC harboring MET exon 14 skipping alterations.

For more information on these studies, visit ClinicalTrials.gov and search identifier NCT01982955 for the Phase Ib/II INSIGHT study, NCT03940703 for the Phase II INSIGHT 2 study or NCT02864992 for the Phase II VISION study.

*Tepotinib is the recommended International Nonproprietary Name (INN) for the MET kinase inhibitor (MSC2156119J). Tepotinib is currently under clinical investigation and not approved for any use anywhere in the world.

About Non-Small Cell Lung Cancer

With 2 million cases diagnosed annually, lung cancer (including trachea, bronchus and lung) is the most common type of cancer worldwide, and the leading cause of cancer-related death, with 1.7 million mortality cases worldwide.3 Alterations of the MET signaling pathway, including MET exon 14 skipping alterations and MET amplifications, occur in 3-5% of NSCLC cases.4-6

About Tepotinib

Tepotinib, discovered in-house at Merck KGaA, Darmstadt, Germany, is an investigational oral MET inhibitor that is designed to inhibit the oncogenic MET receptor signaling caused by MET (gene) alterations, including both MET exon 14 skipping alterations and MET amplifications, or MET protein overexpression. It has been designed to have a highly selective mechanism of action, with the potential to improve outcomes in aggressive tumors that have a poor prognosis and harbor these specific alterations.

Tepotinib is currently being investigated in NSCLC and Merck KGaA, Darmstadt, Germany is actively assessing the potential of investigating tepotinib in combination with novel therapies and in other tumor indications.

References

1. Yang J, et al. AACR 2019 abstract CT193; NCT01982955.

2. Paik P, et al. J Clin Oncol 2019;37: (suppl; abstr 9005).

3. Bray F, et al. CA Cancer J Clin. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492 PMID:30207593

4. Reungwetwattana T, et al. Lung Cancer 2017;103:27-37.

5. Mo HN, et al. Chronic Dis Transl Med 2017; 3(3):148-153.

6. Lutterbach B, et al. Cancer Res 2007;67:2081-8.

Disclaimer

Merck KGaA published this content on 09 September 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 September 2019 12:36:03 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
11:23aMERCK : Progyny Inc. Sets IPO at 10 Million Shares; Sees Pricing at $14-$16 Each
DJ
02:48aJ&J's Courtroom Losses Pile Up -- WSJ
DJ
10/14MERCK : Drugmaker to Test Machine Learning to Prevent Drug Shortages
DJ
10/14Johnson & Johnson's Legal Challenges Mount
DJ
10/10Germany's Merck KGaA Acquires FloDesign Sonics
DJ
10/10MERCK : MilliporeSigma Becomes the First to Use Acoustic Technology for Cell The..
PU
10/09Massive jury award against J&J highlights risks of its legal strategy
RE
10/09MERCK : EMD Serono Announces JAMA Publication of Phase II Results of Sprifermin ..
AQ
10/08MERCK : Darmstadt, Germany, Expands and Modernizes Pigments Production
PU
10/08MERCK : Darmstadt, Germany, Announces JAMA Publication of Phase II Results of Sp..
PU
More news
Financials (EUR)
Sales 2019 15 635 M
EBIT 2019 2 246 M
Net income 2019 1 483 M
Debt 2019 6 211 M
Yield 2019 1,28%
P/E ratio 2019 30,3x
P/E ratio 2020 24,0x
EV / Sales2019 3,29x
EV / Sales2020 3,02x
Capitalization 45 282 M
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 104,82  €
Last Close Price 103,65  €
Spread / Highest target 28,5%
Spread / Average Target 1,13%
Spread / Lowest Target -20,9%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Member-Supervisory Board
Michael Fletterich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA15.75%49 903
KYOWA KIRIN CO., LTD.-3.21%9 715
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD24.51%9 206
JAZZ PHARMACEUTICALS PLC-5.09%6 661
BETTA PHARMACEUTICALS CO LTD--.--%2 872
YUHAN CORP--.--%2 202